SCHEMBL22191123

SCHEMBL22191123

O=C(Nc1ccccc1)c1ncc(-c2ccc3[nH]c(=O)[nH]c3c2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ MAP4K4 O95819 2/20 0.47
▸ CDK1 P06493 2/20 0.47
▸ CDK2 P24941 2/20 0.47
▸ MARK3 P27448 2/20 0.47
▸ GSK3B P49841 2/20 0.47
▸ CSNK1G2 P78368 2/20 0.47
▸ CDK5 Q00535 2/20 0.47
▸ MAP4K2 Q12851 2/20 0.47
▸ CAMK2D Q13557 2/20 0.47
▸ MARK2 Q7KZI7 2/20 0.47
▸ MINK1 Q8N4C8 2/20 0.47
▸ SLK Q9H2G2 2/20 0.47
▸ CLK4 Q9HAZ1 2/20 0.47
▸ MKNK2 Q9HBH9 2/20 0.47
▸ MAP4K5 Q9Y4K4 2/20 0.47
▸ PLK4 O00444 1/20 0.47
▸ CHEK1 O14757 1/20 0.47
▸ PRKD3 O94806 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22191681 0.81 CCNC (0.54) MAPTALDH1A1KDM4EMCL1PDE3B
SCHEMBL22191685 0.79 RET (0.51) MAPTALDH1A1MAP4K4CDK1CDK2
SCHEMBL22191487 0.76 MAPT (0.49) MAPTALDH1A1MAP4K4CDK1CDK2
SCHEMBL22191704 0.76 CDK7 (0.57) MAPTCDK2GSK3BCLK2DYRK1A
SCHEMBL20772514 0.76 MAPT (0.62) MAPTALDH1A1KDM4EKLK7L3MBTL1
SCHEMBL22191095 0.73 PLK4 (0.50) MAPTMAP4K4CDK1CDK2MARK3
SCHEMBL18190719 0.72 MAPT (0.52) MAPTALDH1A1KDRGRIA1KDM4E
SCHEMBL18190580 0.72 MAPT (0.61) MAPTALDH1A1GRIA1KDM4EL3MBTL1
SCHEMBL15017332 0.72 MCL1 (0.51) MAPTALDH1A1GRIA1MCL1KMT2A
SCHEMBL20773032 0.71 PRKD3 (0.55) MAPTALDH1A1MAP4K4CDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220064146-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-03 — — US disclosed
EP-3906028-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE Icahn School of Medicine at Mount Sinai (US) 2021-11-10 — — EP disclosed
CN-113543783-A Kinase inhibitor compounds and compositions and methods of use 西奈山伊坎医学院 2021-10-22 — — CN disclosed
WO-2020142486-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2020-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220064146-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE CSNK1A1, MAP3K20, CSNK1G3 MAPT 1414/4885ALDH1A1 4521/4885MAP4K4 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback